ARCHIVES

DCCR Merit Review Finds some Excellent contract Projects, Some Not So Good; Some Are Terminated

This article is from The Cancer Letter archive.

Vol. 03 No. 08 | February 25, 1977

Download PDF Visit The Full Archive

Related Articles

NIH Consensus Conference Agenda, Registration Online.

September 1, 2000

NCI Programs: Advisors Approve Recompetition of Phase II Contracts

July 9, 1999

NCI Puts Aside Fear Of Brockovich Factor To Open New Web Site On Mortality Data.

April 20, 2001

NCI Bypass Budget Seeks $3.64 Billion

January 20, 1995

The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.

May 7, 2004

House Aims to End Budget Markup Early; Natcher Sees Most Difficult Year

June 26, 1992